Background-Nonadherence to prescribed evidence-based medications after acute myocardial infarction (MI) can contribute to worse outcomes and higher costs. We sought to better understand the modifiable factors contributing to early nonadherence of evidence-based medications after acute MI. Methods and Results-We assessed 7425 acute MI patients treated with percutaneous coronary intervention at 216 US hospitals participating in TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) between April 2010 and May 2012. Using the validated Morisky instrument to assess cardiovascular medication adherence at 6 weeks post MI, we stratified patients into selfreported high (score, 8), moderate (score, 6-7), and low (score, <6) adherence groups. Moderate and low adherence was reported in 25% and 4% of patients, respectively. One third of low adherence patients described missing doses of antiplatelet therapy at least twice a week after percutaneous coronary intervention. Signs of depression and patientreported financial hardship because of medication expenses were independently associated with a higher likelihood of medication nonadherence. Patients were more likely to be adherent at 6 weeks if they had follow-up appointments made before discharge and had a provider explain potential side effects of their medications. Lower medication adherence may be associated with a higher risk of 3-month death/readmission (adjusted hazard ratio, 1.35; 95% confidence interval, 0.98-1.87) although this did not reach statistical significance. Conclusions-Even early after MI, a substantial proportion of patients report suboptimal adherence to prescribed medications. Tailored patient education and pre discharge planning may represent actionable opportunities to optimize patient adherence and clinical outcomes. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01088503.
C ardiovascular disease is one of the leading causes of morbidity and mortality in the United States, 1 yet rates of mortality associated with coronary artery disease have declined in recent years. This decline has been partially attributed to the use of evidence-based therapies, such as aspirin, ADP receptor inhibitors, β-blockers, and statins, that reduce risks of recurrent cardiovascular adverse events. 2, 3 National inpatient registries demonstrate high prescription rates of these medications at discharge from the index myocardial infarction (MI) hospital 4, 5 ; however, a prescription does not necessarily translate into continued adherence to a prescribed regimen. Previous literature has shown that patient adherence to prescribed therapies remains poor, with >25% of patients not filling prescription medications within a week after discharge for an acute MI. 6 Medication nonadherence is a widely recognized problem in health care and has been associated with worse patient outcomes and increased healthcare costs. [7] [8] [9] Nonadherence to antiplatelet therapy after percutaneous coronary intervention (PCI) is of particular concern because of the increased risk of stent thrombosis. 10 Therefore, a better understanding of modifiable factors contributing to nonadherence may help inform actionable opportunities to optimize longitudinal patient outcomes.
The TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study is a longitudinal observational study of PCI-treated patients with MI that rigorously assesses adherent behaviors via a validated, 8-question Morisky Medication Adherence Scale (MMAS). [11] [12] [13] The reasons for poor medication adherence are probably multifactorial. TRANSLATE-ACS collects detailed information on patient sociodemographic, economic, and clinical factors, as well as assesses the quality of patientprovider interactions. As a result, TRANSLATE-ACS offers a unique opportunity to (1) determine the incidence and degree of cardiovascular medication nonadherence early after hospital discharge in a contemporary PCI-treated MI population;
(2) evaluate patient and provider factors independently associated with cardiovascular medication nonadherence; and (3) assess the association of medication nonadherence on subsequent mortality and readmission risk.
Methods

Study Design and Population
TRANSLATE-ACS is a longitudinal observational study of MI patients treated with PCI and antiplatelet therapy (clinical trial No. NCT01088503). The study design, including a detailed description of patient follow-up and data collection, has been previously described. 14 Briefly, this study of ST-segment-elevation MI and non--ST-segment-elevation MI patients who were treated with PCI and started on an ADP receptor inhibitor during the index hospitalization was broadly inclusive, excluding only those patients who were unable or unwilling to provide written informed consent for longitudinal follow-up, or who were simultaneously participating in another research study that specified use of a specific antiplatelet agent within the first 12 months post MI. The Institutional Review Board of each reporting hospital approved participation in TRANSLATE-ACS, and all data were collected prospectively.
Post discharge study follow-up was conducted via centralized telephone interviews by trained personnel at the Duke Clinical Research Institute. During the 6-week interview, patients were administered the 8 MMAS questions to evaluate self-reported medication adherence. At both 6-week and 6-month interviews, patients were asked to report any rehospitalizations. All self-reported rehospitalizations were verified by the collection of hospital bills. As a safeguard against under-reporting, all enrolling hospitals were queried at 12 months for any rehospitalizations that may not have been reported by the patient. For this analysis, we included all patients enrolled in TRANSLATE-ACS among 216 US hospitals from April 2010 to May 2012 who were alive to complete the follow-up interviews at 6 weeks (n=8488). We excluded patients who had incomplete answers to the MMAS questions (n=625), those who were lost to follow-up at 6 months (n=280), and those whose reported rehospitalizations that could not be validated by medical bill collection (n=158). Our final study population consisted of 7425 patients.
Data Collection and Definitions
Participating hospitals collected information on baseline demographic and clinical characteristics, processes of care, and inhospital outcomes using a standardized set of data elements and definitions, aligned with those used by the National Cardiovascular Data Registry. 14 Patients were contacted by telephone at 6 weeks and at 6 months post discharge to collect additional information on medication use, patient-provider communication, quality of life, and follow-up care. We evaluated patient self-reported adherence to prescribed cardiovascular medications at the 6-week telephone interview by administering the MMAS. [11] [12] [13] We assessed functional status using the validated EuroQol-5 Dimensions (EQ-5D) score, 15 whereas depression was measured using the Patient Health Questionnaire-2. 16 Three previously validated questions assessing health literacy (Table 1) were added to version 2 of the 6-week follow-up interview case report form 17, 18 ; consequently, data on health literacy were captured in 54% of the study population. All rehospitalizations were verified by the collection of hospital bills or medical records. All deaths were verified by hospital bills, medical records, or the national death index.
Statistical Methods
We used answers from the MMAS (1 point for each question shown in Table 2 ) to stratify the study population into high (score, 8-answered no to all questions), moderate (score, 6-7), and low (score, <6) medication adherence groups. 11 We chose the cut points of high, moderate, and low because they have been previously shown in validated models to be clinically useful. 11 Patient characteristics and outcomes in each group were described using frequencies and percentages for categorical variables and median values (with 25th and 75th percentiles) for continuous variables. Characteristics of patients in each group were compared using χ 2 tests for categorical variables and Wilcoxon rank sum tests for continuous variables. Overall, 7.4% of data were missing.
Multivariable logistic regression modeling was used to determine baseline demographic and discharge factors associated with patientreported medication nonadherence at 6 weeks (MMAS score, <8). We hypothesized that patient characteristics (particularly those related to socioeconomic and health status [eg, physical function and depression]), as well as provider factors (such as those related to communication and follow-up), contribute significantly to the likelihood that a patient will be adherent to prescribed medications after discharge. Therefore, patient-level covariates selected for inclusion in the model were age, sex, black race, non-Hispanic ethnicity, educational level achieved, marital status, employment status, private
WHAT IS KNOWN
• Nonadherence to prescribed medications after an acute myocardial infarction is not uncommon and is associated with poor clinical outcomes and high healthcare costs
WHAT THE STUDY ADDS
• Medication nonadherence remains common (in ≤one third of patients) soon after a myocardial infarction. • We found modifiable factors such as depression, perceived financial hardship, provider communication, and prescheduled follow-up after discharge were associated with the likelihood that a patient would be adherent or nonadherent to therapies. • Low adherence was associated with a nonsignificant increase in adverse outcomes. • The reasons for nonadherence are complex and span multiple domains, including sociodemographics and modifiable factors like those related to patient motivation and provider communication. Long-term solutions to address the problem of poor medication adherence should be tailored to specific patient needs that can be identified before discharge. insurance coverage, current smoker, EQ-5D score, Patient Health Questionnaire-2 depression score, self-reported financial hardship obtaining prescription medications, and medication copayment assistance program participation. As a healthy adherer effect may be evident, 19, 20 we further adjusted for self-reported engagement in routine exercise (exercised at least 20 minutes daily). Pre discharge providerlevel factors entered into the model included cardiac rehabilitation referral and follow-up appointment made before discharge, written list of discharge medication with instructions provided at hospital discharge, and provider explanation of medication rationale and potential side effects. Missing values of the continuous variables were imputed to the median and missing values of categorical variables were imputed to the mode. We used a composite end point of death or all-cause readmission from the 6-week interview out to 6 months among patients with high, moderate, and low cardiovascular medication adherence. For time-to-event analyses, all events occurring before the 6-week interview were censored. The event rates for death or all-cause readmission were estimated using Kaplan-Meier analysis, and log-rank P values were calculated to compare outcomes between groups. For adjusted analyses comparing outcomes between low adherence and other groups, multivariable Cox regression modeling was used to estimate the hazard ratio and 95% confidence intervals. Variables in the adjustment model were adapted from previous MI risk adjustment models. 21, 22 The TRANSLATE-ACS study was funded by Daiichi Sankyo, Inc and Eli Lilly & Company. All data analyses were performed independently by statisticians at the Duke Clinical Research Institute using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Among 7425 acute MI patients, 5278 (71%) reported being highly adherent to prescribed cardiovascular medications, 1845 (25%) reported moderate adherence (1350 had a Morisky score of 7 and 495 patients had a Morisky score of 6), and 302 (4%) reported low adherence by 6 weeks after their MI. As shown in Table 2 , 82% of patients with low medication adherence reported sometimes forgetting to take his/her 
Baseline Characteristics and In-Hospital Treatment
From a sociodemographic standpoint, patients with low cardiovascular medication adherence were more often younger, unmarried, or used, and were less often high school graduates or had healthcare insurance, compared with patients with high medication adherence (Table 1) . When compared with highly adherent patients, those with low medication adherence were more often smokers, and more often had diabetes mellitus or dyslipidemia, a previous MI or PCI, and a previously treated culprit lesion. During the index MI hospitalization, we found no difference in the use of drug-eluting stents between the 3 groups. Notably, patients with low medication adherence more often admitted limitations in their ability to learn about their medical condition because of difficulty understanding written health information; this finding suggests that patients with low medication adherence have lower health literacy compared with patients with higher medication adherence.
Discharge and Post Discharge Processes
There were no significant differences in the number of medications prescribed at discharge between groups ( Table 3 ). The large majority of patients (95.7%) received written discharge medications and instructions. Nevertheless, when compared with highly adherent patients, those with lower adherence were less likely to report a provider explaining the rationale and potential side effects for each medication. There were no significant differences in the rates of followup appointments arranged before discharge between adherence groups, yet patients with lower medication adherence were less likely to visit any physician within the first 6 weeks post MI (Table 3 ). Compared with highly adherent patients, those with lower medication adherence were less likely to exercise regularly and to know their most recent home blood pressure measurement.
Pill boxes, calendars, or other tools to help keep track of medications were commonly used (65%) in this study population and were used similarly among the groups. Patients with lower medication adherence were less likely to know what to do when a medication ran out. Notably, when these post-PCI patients were asked about the frequency of missing an ADP receptor inhibitor dose, 8% of moderate adherence patients and 33% of low adherence patients reported missing a dose at least twice a week. The majority of patients (88%) had insurance or a prescription assistance program to help support payment of medication expenses; however, patients with lower adherence were more likely to report financial hardship paying for medications and were less likely to have prescription assistance coverage.
Independent Factors Associated With Nonadherence
After multivariable modeling, baseline factors significantly associated with medication nonadherence at 6 weeks are presented in the Figure 1 . We found that patient-reported financial hardship because of medication expenses and depression were associated with a higher likelihood of medication nonadherence. Patients who had followup appointments made before discharge and those who reported having a provider explain potential side effects of their medications were more likely to be adherent at 6 weeks. Interestingly, although increasing age was associated with greater medication adherence, we found that other demographic variables such as race and ethnicity were not. Those who engaged in regular exercise post discharge were more likely to be adherent; however, cardiac rehabilitation participation was not independently associated with medication adherence.
Longitudinal Outcomes
The median duration of follow-up post discharge was 164 days (25th and 75th percentiles, 156-175). Between the 6-week interview and 6-month follow-up, there were an additional 66 deaths and 1573 readmissions. Unadjusted event curves for patients with moderate and high medication adherence tracked closely throughout the entire 6-month post MI period ( Figure 2 ). Event curves diverged early for patients with low medication adherence (Figure 2) . At 60 days, the risk of death or readmission was higher among patents with low medication adherence, but did not reach statistical significance in unadjusted (log-rank P value, 0.049) and multivariable adjusted comparisons (adjusted hazard ratio, 1.35; 95% confidence interval, 0.98-1.87) than patients with moderate/ high adherence. The curves converged later such that 6-month post MI event rates were similar between all groups (Figure 2 , unadjusted log rank P value, 0.59; adjusted hazard ratio, 1.02; 95% confidence interval, 0.80-1.30).
Discussion
In this large, multicenter study of MI patients treated with PCI, ≈30% of patients reported suboptimal adherence to prescribed cardiovascular medications in the first 6 weeks after their MI hospitalization. Nonadherent patient behavior may be associated with early mortality and readmission risks. Although some nonmodifiable socioeconomic and clinical factors are associated with nonadherence, our results suggest several opportunities for provider intervention.
Medication Adherence Remains Suboptimal Early After MI
As early as 6 weeks after a hospitalization for MI, we found that ≈30% of contemporary MI patients are suboptimally adherent to prescribed cardiovascular medications. This rate has not changed significantly compared with earlier studies. 6, 23, 24 In 2008, Jackevicius et al 6 found that nearly 25% of patients do not fill prescriptions for cardiac medications early after an MI discharge with little improvement 4 months later. Previous studies have also noted steady declines in β-blocker and statin use over time to <50% use by 12 months after a cardiac procedure. 25 Post-PCI, optimal adherence to dual antiplatelet therapy is critical, as its premature discontinuation increases the risk of stent thrombosis, MI, and death. 2,3,10,26 In our study, medication adherence was self-reported using the MMAS and may, in fact, underestimate true adherence given pitfalls such as recall bias. Of concern, one third of patients in the low adherence group reported missing doses of prescribed ADP receptor inhibitor at least twice a week. This highlights the continuing challenge and opportunity for improvement in ensuring the optimal medical management of patients after MI and PCI.
Implications of Low Medication Adherence
Medication nonadherence is a widespread problem across healthcare and may reflect discrepancies between provider and patient perception of treatment benefits. For instance, asymptomatic conditions such as hypertension and hyperlipidemia have been associated with suboptimal medication adherence in part because patients think they do not feel any different on or off medications. [27] [28] [29] [30] Even after an acute MI, patients who do not perceive a beneficial effect of taking medications are less likely to be adherent to secondary prevention medications. 31 Therapies with noticeable (even if minor) side effects (eg, easy bruising with antiplatelet therapy) or those with less apparent health impact (eg, statin therapy) are particularly vulnerable to nonadherence. 29 Our results show that a substantial proportion of low adherence patients reported self-discontinuation of medications if they thought it made them feel poorly or if they perceived that their cardiac condition had improved. Although one might hypothesize that patients with a first-time MI might have more difficulty with adherence compared with patients previously hospitalized for a similar event, our results actually show a higher prevalence of previous MI among those with lower medication adherence. Lack of adherence to secondary preventative care contributes to a greater likelihood of disease recurrence and treatment complications, 32 and may be a driver of increased healthcare costs. 33 Previous studies have linked poor medication adherence after MI with higher risks of readmission and mortality. 34, 35 In our study, event curves appeared to initially diverge, but then converged later such that 6-month death/readmission risks were similar between groups. Potential explanations for this finding include (1) a smaller number of low adherence patients limits the power to show significant differences between groups; and (2) adherent behavior may change over time with more patients crossing over to lower adherence after 6 months. Figure 1 . Forest plot. This figure displays significant factors associated with medication nonadherence. Other variables included in the model: sex, non-Hispanic, black race, smoker, cardiac rehab referral, EuroQol-5 Dimensions score, married, ≥high school graduation, employed, written discharge medication list/instructions, insurance coverage, assistance program to pay for medications, cardiac rehab participation. Moderate exercise=at least 1 day a week of ≥20 minutes of exercise. Odds ratio listed with 95% confidence intervals PHQ indicates patient health questionnaire.
Figure 2.
Rates of death/readmission. Kaplan-Meier curves for rates of death/readmission within 120 days according to Morisky score. Variables included in the model: age, sex, race, ethnicity, insurance status, marital status, educational level, previous myocardial infarction (MI), previous percutaneous coronary intervention (PCI), previous coronary artery bypass graft surgery (CABG) surgery, previous stroke or transient ischemic attack, peripheral arterial disease, previous heart failure, previous atrial fibrillation or flutter, diabetes mellitus, hypertension, dyslipidemia, dialysis, smoking status, chronic lung disease, recent gastrointestinal, or genitourinary bleeding in the 6 months before index MI admission, ST-segment-elevation myocardial infarction presentation, cardiac arrest within 24 hours of admission, cardiogenic shock within 24 hours of admission, heart failure signs or symptoms within 2 weeks before admission, body mass index, admission heart rate, admission systolic blood pressure, preprocedure hemoglobin, preprocedure creatinine clearance, multivessel disease on angiography, multivessel PCI, bifurcating culprit lesion, culprit lesion involving a CABG graft, drug-eluting stent implantation, culprit lesion successfully dilated, left ventricular ejection fraction, transfer-in status, number of hospitalizations between index hospital discharge and the 6-week interview, and hospital referral region. July 2015
Potential Solutions
A major strength of our study was the ability to examine a breadth of potential patient and provider factors associated with adherence. These factors can broadly be categorized into motivational (ie, exercise, tobacco use, and home blood pressure monitoring), communication-related (ie, written instructions, provider explanation of side effects, and health literacy), and socioeconomic factors (ie, cost). 29 As the reasons for medication nonadherence are multifactorial, effective, and sustainable solutions must be multimodal and simultaneously address these various facets of nonadherence. [36] [37] [38] For example, patient tools such as pillboxes and written discharge medication lists have been shown to be highly effective in improving medication adherence. 39, 40 In our study, these tools were commonly used but, in and of themselves, did not predict high medication adherence. In a recent qualitative assessment, patients with MI most frequently cited poor communication and education on the need or importance of specific therapies as reasons for premature medication cessation. 41 This finding is consistent with our results in that patients who had low adherence cited poor communication of the need and reasons for each of the discharge medications, as well as the possible side effects that they may encounter. Provider explanation of potential side effects of the medications prescribed at discharge was independently associated with better short-term adherence. Our study also shows the importance of assessing health literacy when disseminating written patient instructions and educational materials.
We found follow-up appointment arrangement before discharge to be strongly associated with adherence. Lack of contact represents a lost opportunity not only for reinforcing continued treatment goals but also for assessing medication intolerance and patient knowledge gaps that might contribute to nonadherence. We found that patients with low adherence were also less likely to engage in healthy behaviors such as home blood pressure monitoring or routine exercise, and were more often smokers compared with medium or high adherence patients. Among the patient characteristics included in our multivariate model, we found that those who exercised on a routine basis were nearly 30% more likely to be adherent on short-term follow-up. These results affirm the healthy adherer effect hypothesis, which suggests that the lower risk of adverse outcomes in patients with high adherence may be a surrogate for overall healthier behavior. 19, 20 Creative multimodality solutions bridging the gap between hospital discharge and outpatient follow-up that engage a patient's interest in his or her own healthcare may represent the greatest opportunity for success. Interventions that foster continued consistent communications between patients and the healthcare system, such as telemonitoring 42 or pharmacist interactions, 43 have been recommended for conditions beyond acute MI.
We found that nonadherent patients were more likely to report financial hardship because of medication costs. In the Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) trial, Choudhry et al 44 found that reducing patient copayments was associated with improved medication use. Strategies such as this, which are referred to as value-based insurance design, hope to improve longterm adherence. In our study, highly adherent patients more often reported coverage of medication costs by their insurance. Notably, improvements in adherence in MI FREEE were modest with copayment reduction alone, suggesting that additional measures are needed to improve medication-taking behavior and outcomes.
Our study had several limitations. First, medication adherence was patient-reported and, therefore, was not verified by pill count. Nevertheless, the MMAS is a validated questionnaire that has demonstrated good correlation to quantified monitoring methods and provides a more feasible alternative to assess adherence in real-world practice. Also, adherence was assessed only at 1 time point and, consequently, may not be reflective of downstream adherence. Similarly, patients who died before the 6-week follow-up interview were not included in the final study population; therefore, early nonadherence could be under-reported. Second, although this study goes beyond typical databases in collecting potential patient-reported barriers to adherence, recall bias is a limitation especially when evaluating patient-reported engagement in exercise or recollection of provider instructions. It is also possible that participants in a research study may be more likely to maintain adherent behaviors than individuals in the general population. Third, even after adjustment for baseline differences, unmeasured confounding must be considered when interpreting these results. In addition, a causal relationship cannot be inferred between adherence and risk of long-term outcomes such as death and rehospitalization in this observational analysis. Finally, the study population consisted of patients with MI entered from sites participating in TRANSLATE-ACS, so all patients underwent PCI. Early adherence rates may differ in other patients and settings.
In conclusion, adherence to prescribed therapies remains suboptimal for contemporary MI patients, and may be related to worse long-term outcomes. Although certain socioeconomic and clinical factors are particularly associated with medication nonadherence, our study highlights several potentially modifiable factors that may provide opportunities for intervention. Tailored patient education and pre discharge planning, as well as the availability of continued patient interactions with the health system early after hospital discharge, may represent key actionable opportunities to optimize patient adherence and improve outcomes.
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